CannaPharmaRX, Inc.
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- CannaPharmaRX, Inc. (CPMD) is a Canada-based cannabis company focused on the cultivation, production, and export of high-quality medical cannabis, craft products, and customizable cannabinoid formulations; it offers over 200 unique genetic strains across 15 brand classes, including dried cannabis flower, terpene-rich medical cannabis, small-batch craft cannabis, and on-demand CBD oil production. The company operates a 55,000 square foot facility in Cremona, Alberta, with an annual production capacity exceeding 6,000 kilograms, and holds Health Canada standard cultivation/processing licenses along with a CRA cannabis license obtained in December 2022. Founded in 1998 and headquartered in Calgary, Alberta, CannaPharmaRX targets medical and recreational markets in Canada, Europe (including Germany), Israel, and Latin America through strategic partnerships and export agreements. Recent developments include the opening of a sixth growing room in September 2025 to meet rising demand and support expansion toward a total of ten grow rooms; projection of Q3 2025 revenues exceeding CAD $1 million from ongoing cannabis exports. In 2024, the company completed its first shipment to Germany, secured a multi-million dollar supply agreement with Cantek in Israel, received multiple purchase orders leading to product deliveries, and entered a $12 million collaboration with Spring Medical Group alongside a genetics transfer agreement with a high-profile cannabis corporation. Additional strategic moves encompass a letter of intent to acquire an Oklahoma cannabis facility, board strengthening with expert appointees, and efforts toward EU-GMP certification to facilitate European market penetration, with Q1 2024 financial results highlighting foundational progress in licensing, joint ventures, and pre-sales partnerships.
CannaPharmaRX Provides Corporate Update and Outlines Growth Strategy for 2026
CannaPharmaRX Expands Cannabis Exports, Projects $1M+ Q3 Revenue
CannapharmaRx Continues into New European Market with First Shipment Completed to Germany
CannapharmaRx to Complete Additional Shipment in November
CannaPharmaRx Receives Multiple Purchase Orders and Begins Delivery of Product
Q1 2024 Financial Results
CORRECTION FROM SOURCE: CannaPharmaRx to Host Investor Conference Call
CannaPharmaRx to Host Investor Conference Call
CannapharmaRx Pays Off Convertible Notes
CannapharmaRx Receives First Purchase Order and Begins Shipment of Product
CannaPharmaRx Completes First Harvests
CannaPharmaRx to Hold Investor Conference Call
CannaPharmaRx Executes Multi-Year Supply Agreement with ICAN to Create Distribution Network in the Latin Americas
CannaPharmaRx Achieves IMC-GAP and GACP Certifications Completing a Significant Milestone Towards Revenue Acceleration
CannaPharmaRx Finalizes Multi-Million Dollar Israeli Supply Agreement with Cantek
CannaPharmaRx CEO Provides Annual Update Message
CannaPharmaRx Expands Board of Directors
CannaPharmaRX, Inc. Closes Sale of Hanover Facility for $2,000,000 CAD
CannaPharmaRx Comments on Stock Promotion Flag
CannaPharmaRX, Inc. Signs Agreement with Israeli Group K&K Consulting